Drugs / IFN-α
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04749368 | Apr 2021 → Jul 2023 | chronic hepatitis B virus infection | Brii Biosciences Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-11-13 | Vir Biotechnology, Inc. | Results Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023 vir.bio ↗
Specifically, at 24 weeks, 15.0% and 14.3% of participants achieved HBsAg loss at EOT for VIR-3434 + VIR-2218 and VIR-2218 + VIR-3434 + PEG-IFN-α, respectively. |
| 2023-07-06 | Brii Biosciences Limited | Results Brii Biosciences Provides Latest Clinical Development and Corporate Updates briibio.com ↗
Anti-HBs titers greater than 500 mIU/mL at the end of treatment were associated with sustained HBsAg loss at 24 weeks after the end of treatment. |
| 2022-11-06 | Vir Biotechnology, Inc. | Results Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection vir.bio ↗
Additionally, 48 weeks of VIR-2218 plus PEG-IFN-α provided greater reductions in hepatitis B surface antigen (HBsAg) (mean decrease of -2.9 log10 IU/mL) compared to VIR-2218 alone or with shorter regimens of the combination. |
| 2021-04-12 | VBI Vaccines Inc. | Results VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate vbivaccines.com ↗
VBI-2601 (BRII-179) was well-tolerated at all dose levels with and without IFN-α, with no significant adverse events identified |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-11-13 | Vir Biotechnology, Inc. | Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023 vir.bio ↗ |
| 2023-07-06 | Brii Biosciences Limited | Brii Biosciences Provides Latest Clinical Development and Corporate Updates briibio.com ↗ |
| 2022-11-06 | Vir Biotechnology, Inc. | Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection vir.bio ↗ |
| 2021-04-12 | VBI Vaccines Inc. | VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate vbivaccines.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IFN-α | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04749368 ↗ |
| Route | Intramuscular | “BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection” NCT04749368 ↗ |